Segnalazione PI3K/Akt/mTOR
Gli inibitori della segnalazione PI3K/Akt/mTOR sono composti che bersagliano le vie della fosfoinositide 3-chinasi (PI3K), della chinasi Akt e del bersaglio della rapamicina nei mammiferi (mTOR). Queste vie sono regolatori critici della crescita cellulare, della sopravvivenza, del metabolismo e dell'autofagia, rendendole bersagli chiave nella ricerca sul cancro e nei disturbi metabolici. Inibendo queste vie è possibile aiutare a controllare la crescita e la proliferazione tumorale, offrendo potenziali strategie terapeutiche per vari tipi di cancro e altre malattie caratterizzate da una segnalazione cellulare disfunzionale. Presso CymitQuimica, offriamo una vasta selezione di inibitori PI3K/Akt/mTOR di alta qualità per supportare la tua ricerca in oncologia, segnalazione cellulare e malattie metaboliche.
Sottocategorie di "Segnalazione PI3K/Akt/mTOR"
- AMPK(159 prodotti)
- ATM/ATR(71 prodotti)
- DNA-PK(50 prodotti)
- EGFR(572 prodotti)
- MELK(7 prodotti)
- PDK(9 prodotti)
- PI3K(241 prodotti)
- Chinasi S6(9 prodotti)
- gsk-3(111 prodotti)
- mTOR(144 prodotti)
Mostrare 2 più sottocategorie
Trovati 1030 prodotti di "Segnalazione PI3K/Akt/mTOR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PI3kδ inhibitor 1
CAS:<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Formula:C28H33FN6O2Purezza:98%Colore e forma:SolidPeso molecolare:504.60GSK3-IN-9
CAS:<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Formula:C18H20N4OColore e forma:SolidPeso molecolare:308.378Lys(CO-C3-p-I-Ph)-O-tBu
CAS:<p>Lys(CO-C3-p-I-Ph)-O-tBu, a pharmacokinetic modifier (PK modifier), enhances the pharmacokinetic properties of PSMA ligand molecules by increasing their residence time in plasma through improved binding to albumin and reducing absorption by the salivary glands, potentially extending the active compound's half-life. Moreover, Ac-PSMA-trillium is an effective PSMA-targeting compound for various biological applications when modified with different radioactive isotopes. When labeled with 111 In, it serves as a DOTA chelating agent and imaging agent. Alternatively, when labeled with 225 Ac, it acts as a Macropa chelator for targeted radionuclide therapy (TRT) in researching metastatic castration-resistant prostate cancer (mCRPC) [1] [2].</p>Formula:C20H31IN2O3Colore e forma:SolidPeso molecolare:474.38GSK3β-IN-1
CAS:<p>GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.</p>Formula:C17H13FN2O4SColore e forma:SolidPeso molecolare:360.36SIK2/3-IN-1
CAS:<p>SIK2/3-IN-1 (Compound 7S) is an orally active and selective inhibitor of SIK2/3. It significantly inhibits tumor growth without causing weight loss in the MV4-11 AML mouse CDX model. SIK2/3-IN-1 is applicable for research in MEF2C-dependent acute myeloid leukemia.</p>Formula:C20H19F3N6O2Colore e forma:SolidPeso molecolare:432.399EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Colore e forma:SolidDNA-PK-IN-9
<p>DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.</p>Formula:C21H21N5O2Colore e forma:SolidPeso molecolare:375.42Vulolisib
CAS:<p>Vulolisib inhibits PI3K (α: IC50 0.2nM, β: 168nM, γ: 90nM, δ: 49nM), taken orally with anti-cancer properties.</p>Formula:C18H19F2N5O3SColore e forma:SolidPeso molecolare:423.44PI4KIII β inhibitor 5
CAS:<p>PI4KIII beta inhibitor 5 (Compound 43) is an inhibitor of PI4KIIIβ with an IC50 of 19 nM. By inhibiting the PI3K/AKT pathway, it induces apoptosis in cancer cells, causes cell cycle arrest at the G2/M phase, and promotes autophagy. Additionally, PI4KIII beta inhibitor 5 demonstrates significant anti-tumor activity in the H446 small cell lung cancer xenograft model. This compound is applicable in cancer research studies.</p>Formula:C24H27F2N3O4S2Colore e forma:SolidPeso molecolare:523.616HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColore e forma:SolidPeso molecolare:394.447HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formula:C26H25F2N9O3Colore e forma:SolidPeso molecolare:549.53HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formula:C28H26F3N7O3Colore e forma:SolidPeso molecolare:565.55Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formula:C32H31ClN6O4Colore e forma:SolidPeso molecolare:599.08ETP-47037
CAS:<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Formula:C20H27N9O3SColore e forma:SolidPeso molecolare:473.55EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formula:C27H31N7O3Colore e forma:SolidPeso molecolare:501.58NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C20H16O7Colore e forma:SolidPeso molecolare:368.34GSK-3β inhibitor 25
CAS:<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Formula:C16H15NOSColore e forma:SolidPeso molecolare:269.361Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formula:C31H33Cl2FN4O5SColore e forma:SolidPeso molecolare:663.59EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formula:C26H28ClN3O4Colore e forma:SolidPeso molecolare:481.97PI3K-IN-37
CAS:<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Formula:C25H26N6O2Colore e forma:SolidPeso molecolare:442.51Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formula:C31H36N8O3Colore e forma:SolidPeso molecolare:568.669EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formula:C12H14N4OS2Colore e forma:SolidPeso molecolare:294.4NU5455
CAS:<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Formula:C34H33N3O5SColore e forma:SolidPeso molecolare:595.71EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formula:C27H31ClN7O3PColore e forma:SolidPeso molecolare:568.01EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColore e forma:SolidPeso molecolare:514.58EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formula:C33H28N6O3SColore e forma:SolidPeso molecolare:588.68EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formula:C24H15FO3Colore e forma:SolidPeso molecolare:370.37EGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formula:C13H13N5OColore e forma:SolidPeso molecolare:255.275GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Formula:C27H23BrN4O2SColore e forma:SolidPeso molecolare:547.47EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formula:C21H23N3O5Colore e forma:SolidPeso molecolare:397.424JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formula:C27H20N4O2SPurezza:98%Colore e forma:SolidPeso molecolare:464.54GSK-3β inhibitor 26
CAS:<p>GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.</p>Formula:C15H11N3O3Colore e forma:SolidPeso molecolare:281.266BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formula:C18H15N3O2Colore e forma:SolidPeso molecolare:305.331HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Colore e forma:SolidPeso molecolare:504.58JBJ-09-063
CAS:<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Formula:C31H29FN4O3SColore e forma:SolidPeso molecolare:556.65EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formula:C19H21N3O2SColore e forma:SolidPeso molecolare:355.45SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formula:C22H31ClN4O6Colore e forma:SolidPeso molecolare:482.96EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formula:C30H35FN6O3Colore e forma:SolidPeso molecolare:546.64Neptinib
CAS:<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Formula:C22H23ClFN5O2Colore e forma:SolidPeso molecolare:443.904-FPBUA
CAS:<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Formula:C31H23FO7Colore e forma:SolidPeso molecolare:526.51PI3Kβ-IN-1
CAS:<p>PI3Kβ-IN-1 is a selective, orally active PI3Kβ inhibitor (IC50: 2 nM).</p>Formula:C25H14F2N8Colore e forma:SolidPeso molecolare:464.43GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Formula:C22H21N5O2SColore e forma:SolidPeso molecolare:419.50PI3K-IN-27
CAS:<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Formula:C30H26F2N6O2SColore e forma:SolidPeso molecolare:572.63EGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formula:C27H29F2N7O3Colore e forma:SolidPeso molecolare:537.56LAS195319
CAS:<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Formula:C29H26N10O3SColore e forma:SolidPeso molecolare:594.65EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Formula:C36H44BrN10O3PColore e forma:SolidPeso molecolare:775.68NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Formula:C28H30Cl2F2N6O4Colore e forma:SolidPeso molecolare:623.48DNA-PK-IN-15
CAS:DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.Formula:C23H23N9OColore e forma:SolidPeso molecolare:441.49DNA-PK-IN-2
CAS:<p>DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.</p>Formula:C20H23N5O3Colore e forma:SolidPeso molecolare:381.43EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formula:C31H30FN7OColore e forma:SolidPeso molecolare:535.61
